C34H37N5O5
Neat
595.70
Room Temperature
Ergostine; 2854-38-8; 8RM45QOC5P; (6aR, 9R)-N-[(1S, 2S, 4R, 7S)-7-benzyl-4-ethyl-2-hydroxy-5, 8-dioxo-3-oxa-6, 9-diazatricyclo[7.3.0.02, 6]dodecan-4-yl]-7-methyl-6, 6a, 8, 9-tetrahydro-4H-indolo[4, 3-fg]quinoline-9-carboxamide; Ergotaman-3', 6', 18-trione, 2'-ethyl-12'-hydroxy-5'-(phenylmethyl)-, (5'alpha)-; DTXSID10951231; (6aR, 9R)-N-((1S, 2S, 4R, 7S)-7-benzyl-4-ethyl-2-hydroxy-5, 8-dioxo-3-oxa-6, 9-diazatricyclo(7.3.0.02, 6)dodecan-4-yl)-7-methyl-6, 6a, 8, 9-tetrahydro-4H-indolo(4, 3-fg)quinoline-9-carboxamide; RefChem:137560; DTXCID501379360; UNII-8RM45QOC5P; SCHEMBL25015102; Ergotamine Tartrate EP Impurity C; Ergotamine EP Impurity C (Free Base); ERGOTAMINE TARTRATE IMPURITY C [EP IMPURITY]; Q15410939; (6aR, 9R)-N-((2R, 5S, 10aS, 10bS)-5-benzyl-2-ethyl-10b-hydroxy-3, 6-dioxooctahydro-2H-oxazolo[3, 2-a]pyrrolo[2, 1-c]pyrazin-2-yl)-7-methyl-4, 6, 6a, 7, 8, 9-hexahydroindolo[4, 3-fg]quinoline-9-carboxamide; (6AR, 9R)-N-((2R, 5S, 10AS, 10BS)-5-BENZYL-2-ETHYL-10B-HYDROXY-3, 6-DIOXOOCTAHYDRO-8H-(1, 3)OXAZOLO(3, 2-A)PYRROLO(2, 1-C)PYRAZIN-2-YL)-7-METHYL-4, 6, 6A, 7, 8, 9-HEXAHYDROINDOLO(4, 3-FG)QUINOLINE-9-CARBOXAMIDE; Ergostine; Ergotaman-3', 6', 18-trione, 2'-ethyl-12'-hydroxy-5'-(phenylmethyl)-, (5'a)-; Ergostine (7CI, 8CI); (5'a)-2'-Ethyl-12'-hydroxy-5'-(phenylmethyl)ergotaman-3', 6', 18-trione; (6aR, 9R)-N-[(2R, 5S, 10aS, 10bS)-5-Benzyl-2-ethyl-10b-hydroxy-3, 6-dioxooctahydro-8H-[1, 3]o; ERGOTAMAN-3', 6', 18-TRIONE, 2'-ETHYL-12'-HYDROXY-5'-(PHENYLMETHYL)- and (5'.ALPHA.)-
(6aR, 9R)-N-[(1S, 2S, 4R, 7S)-7-benzyl-4-ethyl-2-hydroxy-5, 8-dioxo-3-oxa-6, 9-diazatricyclo[7.3.0.02, 6]dodecan-4-yl]-7-methyl-6, 6a, 8, 9-tetrahydro-4H-indolo[4 and 3-fg]quinoline-9-carboxamide
InChI=1S/C34H37N5O5/c1-3-33(36-30(40)22-16-24-23-11-7-12-25-29(23)21(18-35-25)17-26(24)37(2)19-22)32(42)39-27(15-20-9-5-4-6-10-20)31(41)38-14-8-13-28(38)34(39,43)44-33/h4-7,9-12,16,18,22,26-28,35,43H,3,8,13-15,17,19H2,1-2H3,(H,36,40)/t22-,26-,27+,28+,33-,34+/m1/s1